A detailed history of Nuveen Asset Management, LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 129,724 shares of ALDX stock, worth $546,138. This represents 0.0% of its overall portfolio holdings.

Number of Shares
129,724
Previous 129,724 -0.0%
Holding current value
$546,138
Previous $429,000 62.94%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$1.47 - $6.06 $82,690 - $340,887
-56,252 Reduced 30.25%
129,724 $455,000
Q3 2023

Nov 14, 2023

BUY
$6.11 - $8.16 $345,355 - $461,227
56,523 Added 43.66%
185,976 $1.24 Million
Q2 2023

Aug 14, 2023

BUY
$7.11 - $11.89 $920,410 - $1.54 Million
129,453 New
129,453 $1.09 Million
Q2 2022

Aug 15, 2022

SELL
$2.43 - $4.85 $576,782 - $1.15 Million
-237,359 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$3.25 - $5.17 $2,151 - $3,422
662 Added 0.28%
237,359 $1.14 Million
Q4 2021

Feb 14, 2022

SELL
$3.5 - $9.63 $42,833 - $117,851
-12,238 Reduced 4.92%
236,697 $1.55 Million
Q3 2021

Nov 12, 2021

SELL
$7.94 - $11.31 $787,568 - $1.12 Million
-99,190 Reduced 28.49%
248,935 $2.13 Million
Q2 2021

Aug 16, 2021

BUY
$10.44 - $14.85 $3.63 Million - $5.17 Million
348,125 New
348,125 $3.94 Million
Q2 2020

Aug 14, 2020

SELL
$1.97 - $5.05 $120,294 - $308,368
-61,063 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$1.62 - $6.4 $126,876 - $501,241
-78,319 Reduced 56.19%
61,063 $150,000
Q4 2019

Feb 14, 2020

BUY
$4.73 - $7.98 $306,801 - $517,606
64,863 Added 87.04%
139,382 $810,000
Q3 2019

Nov 14, 2019

BUY
$4.41 - $6.12 $38,922 - $54,015
8,826 Added 13.44%
74,519 $393,000
Q2 2019

Aug 15, 2019

BUY
$6.0 - $9.0 $394,158 - $591,237
65,693 New
65,693 $394,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $246M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.